$ADMA
ADMA BIOLOGICS, INC.

2021 Q3 Form 10-Q Financial Statement

#000114036121027950 Filed on August 11, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $20.68M $17.83M $7.788M
YoY Change 101.24% 128.96% 18.7%
Cost Of Revenue $20.30M $18.83M $13.50M
YoY Change 71.19% 39.55% 28.64%
Gross Profit $385.3K -$1.002M -$5.708M
YoY Change -124.4% -82.45% 45.23%
Gross Profit Margin 1.86% -5.62% -73.3%
Selling, General & Admin $13.87M $10.44M $9.580M
YoY Change 34.3% 8.96% 43.41%
% of Gross Profit 3600.2%
Research & Development $770.6K $1.159M $1.656M
YoY Change -54.9% -30.04% -17.18%
% of Gross Profit 199.97%
Depreciation & Amortization $1.200M $1.100M $700.0K
YoY Change 33.33% 57.14% 16.67%
% of Gross Profit 311.41%
Operating Expenses $14.82M $14.58M $24.91M
YoY Change -38.44% -41.48% 39.17%
Operating Profit -$14.44M -$15.58M -$17.12M
YoY Change 4.61% -9.01% 51.02%
Interest Expense -$3.294M $3.247M $3.067M
YoY Change -206.57% 5.85% 47.99%
% of Operating Profit
Other Income/Expense, Net $18.55K -$3.324M -$3.054M
YoY Change -100.6% 8.83% 63.05%
Pretax Income -$17.71M -$18.91M -$20.18M
YoY Change 4.69% -6.32% 52.76%
Income Tax
% Of Pretax Income
Net Earnings -$17.71M -$18.91M -$20.18M
YoY Change 4.7% -6.31% 52.73%
Net Earnings / Revenue -85.65% -106.03% -259.11%
Basic Earnings Per Share -$0.13 -$0.15
Diluted Earnings Per Share -$132.4K -$0.15 -$233.7K
COMMON SHARES
Basic Shares Outstanding 132.8M 127.4M
Diluted Shares Outstanding 133.8M 127.4M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $34.41M $42.41M $75.80M
YoY Change -42.36% -44.05% 2.99%
Cash & Equivalents $34.41M $42.41M $75.78M
Short-Term Investments
Other Short-Term Assets $5.859M $5.702M $4.700M
YoY Change 54.19% 21.32% 193.75%
Inventory $114.1M $99.70M $56.00M
Prepaid Expenses
Receivables $20.39M $23.54M $6.514M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $174.8M $171.4M $143.0M
YoY Change 25.25% 19.84% 37.62%
LONG-TERM ASSETS
Property, Plant & Equipment $48.39M $46.49M $37.37M
YoY Change 22.14% 24.39% 27.12%
Goodwill $3.500M $3.500M $3.530M
YoY Change -0.84% -0.84%
Intangibles $2.802M
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.334M $2.527M $4.800M
YoY Change 75.45% -47.36% 71.43%
Total Long-Term Assets $63.86M $61.46M $48.55M
YoY Change 26.63% 26.58% 23.23%
TOTAL ASSETS
Total Short-Term Assets $174.8M $171.4M $143.0M
Total Long-Term Assets $63.86M $61.46M $48.55M
Total Assets $238.6M $232.8M $191.5M
YoY Change 25.62% 21.55% 33.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.28M $6.167M $6.910M
YoY Change 116.58% -10.74% 1.61%
Accrued Expenses $13.03M $10.73M $5.617M
YoY Change 61.36% 91.04% 75.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $32.34M $18.19M $12.88M
YoY Change 96.3% 41.2% 27.53%
LONG-TERM LIABILITIES
Long-Term Debt $94.36M $93.88M $96.60M
YoY Change -2.72% -2.82% 17.23%
Other Long-Term Liabilities $9.160M $9.157M $80.73K
YoY Change 13408.72% 11242.56% -97.93%
Total Long-Term Liabilities $103.5M $103.0M $80.73K
YoY Change 152570.78% 127527.73% -99.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.34M $18.19M $12.88M
Total Long-Term Liabilities $103.5M $103.0M $80.73K
Total Liabilities $135.9M $121.2M $114.7M
YoY Change 14.55% 5.72% 18.94%
SHAREHOLDERS EQUITY
Retained Earnings -$377.8M -$304.1M
YoY Change 24.22%
Common Stock $8.635K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $102.8M $111.6M $76.88M
YoY Change
Total Liabilities & Shareholders Equity $238.6M $232.8M $191.5M
YoY Change 25.62% 21.55% 33.66%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$17.71M -$18.91M -$20.18M
YoY Change 4.7% -6.31% 52.73%
Depreciation, Depletion And Amortization $1.200M $1.100M $700.0K
YoY Change 33.33% 57.14% 16.67%
Cash From Operating Activities -$13.41M -$32.26M -$21.28M
YoY Change -43.76% 51.6% 14.29%
INVESTING ACTIVITIES
Capital Expenditures -$2.789M -$4.477M -$4.170M
YoY Change -3.51% 7.36% 2878.57%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities -$2.789M -$4.477M -$4.170M
YoY Change -3.51% 7.36% 2878.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.203M 17.19M 0.000
YoY Change -22.83% -100.0%
NET CHANGE
Cash From Operating Activities -13.41M -32.26M -21.28M
Cash From Investing Activities -2.789M -4.477M -4.170M
Cash From Financing Activities 8.203M 17.19M 0.000
Net Change In Cash -7.998M -19.55M -25.45M
YoY Change -50.35% -23.17% -144.59%
FREE CASH FLOW
Cash From Operating Activities -$13.41M -$32.26M -$21.28M
Capital Expenditures -$2.789M -$4.477M -$4.170M
Free Cash Flow -$10.62M -$27.78M -$17.11M
YoY Change -49.31% 62.39% -7.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36728
dei Entity Registrant Name
EntityRegistrantName
ADMA BIOLOGICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
56-2590442
dei Entity Address Address Line1
EntityAddressAddressLine1
465 State Route 17
dei Entity Address City Or Town
EntityAddressCityOrTown
Ramsey
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07446
dei City Area Code
CityAreaCode
201
dei Local Phone Number
LocalPhoneNumber
478-5552
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001368514
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
132769471
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q2 adma Cost Of Product Revenue Excluding Amortization Expense
CostOfProductRevenueExcludingAmortizationExpense
18832624
CY2020Q2 adma Cost Of Product Revenue Excluding Amortization Expense
CostOfProductRevenueExcludingAmortizationExpense
13495629
adma Cost Of Product Revenue Excluding Amortization Expense
CostOfProductRevenueExcludingAmortizationExpense
36602746
adma Cost Of Product Revenue Excluding Amortization Expense
CostOfProductRevenueExcludingAmortizationExpense
30324855
dei Document Type
DocumentType
10-Q
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
12792
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
88249426
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
781397
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
41912515
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
112504086
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
805189
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
17189560
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
26193149
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
676548
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
88704039
CY2021Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
83317
CY2020Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
6371
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
125318
CY2021Q1 adma Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes And Retired Amount
VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
-59311
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18379941
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-18905303
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
111593532
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7177
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-19245230
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-20178091
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
76879455
CY2021Q2 adma Accounts Receivable Allowance For Contractual Credits And Doubtful Accounts
AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
200000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
96335683
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
715608
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6255
us-gaap Net Income Loss
NetIncomeLoss
-37285244
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13432
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
12500000
CY2021Q2 adma Working Capital
WorkingCapital
153200000
CY2021Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
42400000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-377800000
CY2020Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
3.50
CY2020Q2 adma Number Of Plasma Collection Facilities Under Development
NumberOfPlasmaCollectionFacilitiesUnderDevelopment
8
CY2020Q2 adma Number Of Fda Licensed Plasma Collection Facilities
NumberOfFDALicensedPlasmaCollectionFacilities
2
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17830590
CY2021Q2 adma Cost Of Product Revenue Excluding Amortization Expense
CostOfProductRevenueExcludingAmortizationExpense
18832624
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15581232
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3324071
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-18905303
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1325994
CY2021Q2 us-gaap Assets
Assets
232813792
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7787594
CY2020Q2 adma Cost Of Product Revenue Excluding Amortization Expense
CostOfProductRevenueExcludingAmortizationExpense
13495629
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17123825
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3054266
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-20178091
CY2020Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
885652
CY2020Q2 us-gaap Assets
Assets
191541568
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33879208
adma Cost Of Product Revenue Excluding Amortization Expense
CostOfProductRevenueExcludingAmortizationExpense
36602746
us-gaap Operating Income Loss
OperatingIncomeLoss
-30745481
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6539763
us-gaap Net Income Loss
NetIncomeLoss
-37285244
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7046735
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2555622
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17987338
adma Cost Of Product Revenue Excluding Amortization Expense
CostOfProductRevenueExcludingAmortizationExpense
30324855
us-gaap Operating Income Loss
OperatingIncomeLoss
-33893611
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5529710
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33879208
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17987338
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6243284
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1674490
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17830590
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7787594
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1723594
us-gaap Interest Paid Net
InterestPaidNet
5534279
us-gaap Interest Paid Net
InterestPaidNet
4192165
adma Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities
EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
1005546
adma Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities
EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
1228000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2844875
CY2020Q4 adma Accounts Receivable Allowance For Contractual Credits And Doubtful Accounts
AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
100000
CY2020Q4 us-gaap Goodwill
Goodwill
3500000
CY2021Q2 us-gaap Goodwill
Goodwill
3500000
CY2020Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12997322
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9265939
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P10Y
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
357676
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
33058221
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
32044393
CY2021Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
49163125
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
30293288
CY2021Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
17478397
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
19197918
CY2021Q2 us-gaap Inventory Net
InventoryNet
99699743
CY2020Q4 us-gaap Inventory Net
InventoryNet
81535599
CY2021Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
6084024
CY2021Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3997579
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2086445
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
6084024
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3639903
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2444121
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
715352
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
50457032
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10955523
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8863942
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46486980
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41593090
CY2021Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1100000
CY2021Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
11490239
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
8365143
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
715352
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
298065
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
57442503
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2200000
CY2020Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
700000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1300000
CY2021Q2 adma Accrued Rebates Current
AccruedRebatesCurrent
3721888
CY2020Q4 adma Accrued Rebates Current
AccruedRebatesCurrent
2604245
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1928901
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
828120
CY2021Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
691483
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
734972
CY2021Q2 us-gaap Liability Premium Deficiency Testing On Long Duration Contract Amount
LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount
1673120
CY2020Q4 us-gaap Liability Premium Deficiency Testing On Long Duration Contract Amount
LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount
779660
CY2021Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1539491
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3210884
CY2021Q2 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
789534
CY2020Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
0
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1145822
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
207262
CY2021Q2 adma Senior Notes Payable Before Debt Discount
SeniorNotesPayableBeforeDebtDiscount
100000000
CY2020Q4 adma Senior Notes Payable Before Debt Discount
SeniorNotesPayableBeforeDebtDiscount
100000000
CY2021Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
6122983
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
7031134
CY2021Q2 us-gaap Senior Long Term Notes
SeniorLongTermNotes
93877017
CY2020Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
92968866
CY2021Q2 adma Senior Notes Payable Before Debt Discount
SeniorNotesPayableBeforeDebtDiscount
100000000.0
adma Repayments Of Debt Interest
RepaymentsOfDebtInterest
5500000
adma Repayments Of Debt Interest
RepaymentsOfDebtInterest
4400000
CY2020Q4 us-gaap Preferred Stock Capital Shares Reserved For Future Issuance
PreferredStockCapitalSharesReservedForFutureIssuance
10000000
CY2021Q2 us-gaap Preferred Stock Capital Shares Reserved For Future Issuance
PreferredStockCapitalSharesReservedForFutureIssuance
10000000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131872026
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
104902888
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
17073357
CY2021Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
151054617
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.82
CY2021Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.82
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
500000
us-gaap Operating Lease Payments
OperatingLeasePayments
200000
CY2021Q2 adma Lessee Operating Lease Liabilities Related To Property Lease
LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease
2800000
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
805189
CY2020Q2 us-gaap Share Based Compensation
ShareBasedCompensation
715608
us-gaap Share Based Compensation
ShareBasedCompensation
1586586
us-gaap Share Based Compensation
ShareBasedCompensation
1392156
adma Plasma Supply Agreement Term
PlasmaSupplyAgreementTerm
P10Y
adma Plasma Purchased
PlasmaPurchased
17500000
adma Percentage Of Inventory Purchases
PercentageOfInventoryPurchases
0.67
adma Plasma Purchased
PlasmaPurchased
3700000
adma Percentage Of Inventory Purchases
PercentageOfInventoryPurchases
0.42
us-gaap Net Income Loss
NetIncomeLoss
-39423321
CY2021Q2 adma Operating Lease Incremental Borrowing Rate Percent
OperatingLeaseIncrementalBorrowingRatePercent
0.13
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
700000
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
300000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4700000
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y3M18D
CY2021Q2 adma Lessee Operating Lease Right Of Use Asset Related To Property Lease
LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease
2800000
CY2021Q2 adma Number Of New Property Leases
NumberOfNewPropertyLeases
3
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
7500000
CY2021Q2 us-gaap Payments For Rent
PaymentsForRent
0
CY2021Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P90M
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
595836
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1512443
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1526406
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1399474
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1405411
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1137321
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
5486813
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
13063704
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5604431
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
385858
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7073415
CY2021Q2 us-gaap Security Deposit
SecurityDeposit
300000

Files In Submission

Name View Source Status
0001140361-21-027950-index-headers.html Edgar Link pending
0001140361-21-027950-index.html Edgar Link pending
0001140361-21-027950.txt Edgar Link pending
0001140361-21-027950-xbrl.zip Edgar Link pending
adma-20210630.xsd Edgar Link pending
adma-20210630_cal.xml Edgar Link unprocessable
adma-20210630_def.xml Edgar Link unprocessable
adma-20210630_lab.xml Edgar Link unprocessable
adma-20210630_pre.xml Edgar Link unprocessable
brhc10027771_10q.htm Edgar Link pending
brhc10027771_10q_htm.xml Edgar Link completed
brhc10027771_ex10-2.htm Edgar Link pending
brhc10027771_ex31-1.htm Edgar Link pending
brhc10027771_ex31-2.htm Edgar Link pending
brhc10027771_ex32-1.htm Edgar Link pending
brhc10027771_ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending